Information Provided By: 
Fly News Breaks for May 2, 2019
ELGX
May 2, 2019 | 21:02 EDT
Piper Jaffray analyst Matt O'Brien kept his Neutral rating and $10 price target on Endologix after its in-line Q1 results. The analyst says investors should monitor signs of "stabilization" in the company's U.S. business amid continued operational risks this year along with its cash burn, adding that the tone of Endologix earnings call was "brighter" but also conservative.
News For ELGX From the Last 2 Days
There are no results for your query ELGX
